Miconazole

證據等級: L5

預測適應症: 1 個

Miconazole: From Antifungal Treatment to Acne

One-Sentence Summary

Miconazole is an imidazole-class antifungal agent widely used to treat fungal and yeast infections of the skin and mucous membranes. The TxGNN model predicts it may be effective for Acne (disease), with 1 clinical trial and 4 publications currently providing supporting evidence for this direction.

Quick Overview

Item	Content
Original Indication	Antifungal (fungal skin infections, mucosal candidiasis)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.54%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Miconazole is an imidazole-class antifungal agent that works primarily by inhibiting ergosterol biosynthesis, disrupting fungal cell membrane integrity. Its original clinical use is well established in treating dermatophyte infections, cutaneous candidiasis, and mucosal yeast infections. Notably, detailed mechanism of action data is not currently available in this Evidence Pack; the following analysis is based on published literature and the TxGNN repurposing rationale.

Three mechanistic pathways link Miconazole to acne: First, in vitro studies have demonstrated that azole-class antifungals, including Miconazole, exhibit direct antibacterial activity against Cutibacterium acnes (formerly Propionibacterium acnes), the key pathogen driving inflammatory acne lesions (PMID 20045949). Second, Miconazole’s well-documented antifungal activity against Malassezia spp. may address Malassezia (Pityrosporum) folliculitis, a condition frequently misdiagnosed as acne vulgaris, expanding its practical utility in acne-like presentations. Third, independent literature reviews document anti-inflammatory adjunct effects of Miconazole nitrate beyond its antifungal mechanism (PMID 18627330), which could theoretically attenuate the inflammatory component of acne.

However, it is important to note that the high TxGNN score (0.9954) is primarily driven by structural associations within the knowledge graph (antifungal → skin condition pathway) rather than direct causal mechanistic evidence. No randomised controlled trial has tested Miconazole as a standalone acne treatment, and the mechanistic link remains at the preclinical/in vitro level.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01244256	Phase 2/3	Suspended	80	Evaluated a triple-combination cream (Beclomethasone 0.025% + Gentamicin 0.1% + Clotrimazole 1%) in patients with contaminated dermatosis showing acne features; not Miconazole-specific and provides no isolatable efficacy data for Miconazole

Note: The only registered trial tests a combination product containing Clotrimazole (not Miconazole), was suspended, and cannot support attribution of any effect to Miconazole alone.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18627330	2008	Narrative Review	Expert Opinion on Pharmacotherapy	Summarises multifaceted skin effects of Miconazole nitrate beyond antifungal action, including anti-inflammatory properties relevant to acne pathophysiology
15536660	2004	Split-face Clinical Study	Skin Research and Technology	Assessed management of mild catamenial (hormonal) acne; Miconazole-containing formulation evaluated in a split-face design; provides limited direct clinical evidence
8593718	1995	Case Series	Clinical and Experimental Dermatology	Pityrosporum folliculitis in 62 patients frequently misdiagnosed as acne vulgaris; Miconazole among antifungals trialled; highlights the diagnostic overlap and potential utility
20045949	2010	In vitro Laboratory Study	Biological & Pharmaceutical Bulletin	Azole antifungals including Miconazole demonstrated inhibitory activity against P. acnes isolates in vitro; minimum inhibitory concentrations reported; no clinical translation data provided

India Market Information

Miconazole currently has no registered products in India. No authorisation numbers, brand names, or approved indications are on file.

Miconazole is a well-established antifungal widely available in many markets (e.g., EU, US, Japan) in topical and oral gel formulations. A regulatory filing would be required for any indication in India, including the predicted acne use.

Safety Considerations

Drug Interactions: A total of 376 drug-drug interactions have been identified. The most clinically significant ones include:

Interacting Drug	Severity	Clinical Relevance
Paclitaxel	Moderate	CYP3A4 inhibition may increase taxane exposure
Fentanyl	Moderate	CYP3A4 inhibition may enhance opioid effects
Acalabrutinib	Moderate	Possible increase in BTK inhibitor plasma levels
Nifedipine	Moderate	Calcium channel blocker levels may be elevated
Ethinylestradiol	Moderate	Potential alteration of oral contraceptive exposure
Alfentanil	Moderate	Opioid metabolism may be impaired
Alfuzosin	Moderate	Risk of hypotension may increase
Amiodarone	Moderate	QTc prolongation risk via CYP inhibition
Amitriptyline	Moderate	Tricyclic antidepressant levels may rise
Amlodipine	Moderate	CYP3A4-mediated interaction possible
Alprazolam	Moderate	Benzodiazepine sedation may be prolonged
Dolutegravir	Minor	Limited clinical significance

Key warnings and contraindications are not available in this Evidence Pack. Please refer to the official package insert for complete safety information before any clinical application.

Conclusion and Next Steps

Decision: Hold

Rationale: Current evidence is at the preclinical/in vitro level (L4), with no completed clinical trial specifically evaluating Miconazole monotherapy for acne. The single registered trial used a different azole (Clotrimazole) in a combination product and was suspended. While the mechanistic hypothesis is biologically plausible, it does not yet meet the threshold for clinical repurposing investment.

To proceed, the following is needed:

Confirm mechanism of action (MOA): Retrieve full DrugBank entry for DB01110 to document the ergosterol-inhibition mechanism and any documented anti-inflammatory or antibacterial activities
Safety baseline: Download and parse the official prescribing information (package insert) to establish key warnings and contraindications before any S1 safety screen
Topical formulation feasibility assessment: Confirm whether existing Miconazole topical formulations (e.g., 2% nitrate cream) achieve sufficient follicular drug concentrations for anti-acne effect
Prospective in vitro / ex vivo study: A controlled in vitro study comparing Miconazole’s anti-C. acnes MIC against standard of care antibiotics (clindamycin, benzoyl peroxide) would be a low-cost next step before any clinical investment
Pilot clinical trial design: If in vitro data supports efficacy, consider a small split-face randomised pilot (n ≈ 30–40) comparing Miconazole 2% cream to vehicle in mild-to-moderate acne vulgaris
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.